Medicus Pharma appoints COO; updates on SKNJCT-003

Philadelphia, USA-based Medicus Pharma (Nasdaq: MDCX) today announced the appointment of Andrew Smith as chief operating officer (COO).

Mr Smith joins Medicus with over three decades of experience and is an accomplished C-suite professional with a successful track record as a leader in asset management and financial operations. Most recently, he was the chief executive of SR Asset Management (SRAM) until its sale in 2024. Before joining SRAM in 2017, he was the co-head of Americas and COO of Aberdeen Asset Management Inc. At Aberdeen, he held various roles including chief compliance officer for their North American Closed End Funds as well as chief financial officer and COO for Aberdeen in the Americas. He currently sits on the board of HazelTree Fund Services and is an advisor to Code Registry.

“We are delighted to welcome Andrew to the leadership team,” stated Dr Raza Bokhari, executive chairman and chief executive of Medicus, adding; “Andrew’s experience and expertise is very relevant and timely, as we expand our business and clinical development operations with active engagements in three continents.”